Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
US1508376076
Tue, 11.06.2024
CEL-SCI Corporation
First Berlin Equity Research has published a research update on CEL-SCI
Corporation (ISIN: US1508376076). Analyst Christian Orquera reiterated his
BUY rating and decreased the price target from USD 8.40 to USD 6.20.
Abstract:
CEL-SCI announced a positive outcome of the type B meeting with the US FDA
for Multikine, its lead drug candidate for ad [ … ]
Wed, 14.02.2024
CEL-SCI Corporation
First Berlin Equity Research has published a research update on CEL-SCI
Corporation (ISIN: US1508376076). Analyst Christian Orquera reiterated his
BUY rating and maintained his USD 8.40 price target.
Abstract:
CEL-SCI announced that it has completed commissioning of its US
manufacturing facility for Multikine, its lead drug candidate for advanc [ … ]
Tue, 05.12.2023
CEL-SCI Corporation
First Berlin Equity Research has initiated coverage on CEL-SCI Corporation
(ISIN: US1508376076). Analyst Christian Orquera's rating is BUY with a
price target of USD 8.40 (€7.70).
Abstract:
CEL-SCI Corporation (CEL-SCI) is a biotech company with a development-stage
immunotherapeutic product pipeline focused on cancer. The company's lead
dr [ … ]